Dilon Technologies

Dilon Technologies is a commercial-stage medical device company with a 20+ year history, operating in over 76 countries. Its core business revolves around a portfolio of surgical technologies, including the MarginProbe system for intraoperative breast cancer margin assessment and HEMOBLAST Bellows for hemostasis. The company positions itself at the intersection of women's health and biosurgery, leveraging a direct commercialization model to serve healthcare providers globally. Its strategy involves both enhancing its established products and developing next-generation iterations.

Portfolio of hardware-based surgical devices for real-time tissue analysis (MarginProbe), hemostasis (HEMOBLAST Bellows), and surgical guidance (Navigator gamma probes).

In margin assessment, Dilon competes with intraoperative ultrasound, specimen radiography, and frozen section pathology. In hemostasis, it faces large competitors like Johnson & Johnson (Surgicel, Ethicon products), Baxter, and Integra. In gamma probes, competition includes Neoprobe and other specialized device makers.